Modulating T Cell Responses by Targeting CD3
Cancers · 13.02.2023 · 15 (4) · 1189
DOI: 10.3390/cancers15041189 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 13.02.2023. Verfasst von Ashwathi Puravankara Menon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Therapeutics Program, Center for Applied Medical Research, CIMA, University of Navarra, 31008 Pamplona, Spain. Die Arbeit wurde bisher 102-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, Marie Skłodowska-Curie ITN.
Abstract (Originalsprache)
Harnessing the immune system to fight cancer has become a reality with the clinical success of immune-checkpoint blockade (ICB) antibodies against PD(L)-1 and CTLA-4. However, not all cancer patients respond to ICB. Thus, there is a need to modulate the immune system through alternative strategies for improving clinical responses to ICB. The CD3-T cell receptor (TCR) is the canonical receptor complex on T cells. It provides the “first signal” that initiates T cell activation and determines the specificity of the immune response. The TCR confers the binding specificity whilst the CD3 subunits facilitate signal transduction necessary for T cell activation. While the mechanisms through which antigen sensing and signal transduction occur in the CD3–TCR complex are still under debate, recent revelations regarding the intricate 3D structure of the CD3–TCR complex might open the possibility of modulating its activity by designing targeted drugs and tools, including aptamers. In this review, we summarize the basis of CD3–TCR complex assembly and survey the clinical and preclinical therapeutic tools available to modulate CD3–TCR function for potentiating cancer immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Molecular Therapeutics Program, Center for Applied Medical Research, CIMA, University of Navarra, 31008 Pamplona, Spain.
- Instituto de Investigación Sanitaria de Navarra (IDISNA), Recinto de Complejo Hospitalario de Navarra, 31008 Pamplona, Spain.
- Unidad Desarrollo y Función del Sistema Inmunitario, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, 28049 Madrid, Spain.
ORCID-Profile: Hisse M van Santen, Fernando Pastor
Förderung
- Instituto de Salud Carlos III
- Spanish Ministry of Science and Innovation
- Marie Skłodowska-Curie ITN
- Feder Funds
- Marie Skłodowska-Curie
- H2020-FETOPEN “DESTINATION”
Zitieren
APA
Menon, A. P., Moreno, B., Meraviglia-Crivelli, D., Nonatelli, F., Villanueva, H., Barainka, M., Zheleva, A., van Santen, H. M., & Pastor, F. (2023). Modulating T Cell Responses by Targeting CD3. Cancers, 15(4), 1189. https://doi.org/10.3390/cancers15041189
Vancouver
Menon AP, Moreno B, Meraviglia-Crivelli D, Nonatelli F, Villanueva H, Barainka M, et al. Modulating T Cell Responses by Targeting CD3. Cancers. 2023;15(4):1189. doi:10.3390/cancers15041189
BibTeX
@article{Menon2023,
author = {Menon, Ashwathi Puravankara and Moreno, Beatriz and Meraviglia-Crivelli, Daniel and Nonatelli, Francesca and Villanueva, Helena and Barainka, Martin and Zheleva, Angelina and van Santen, Hisse M and Pastor, Fernando},
title = {Modulating T Cell Responses by Targeting CD3},
journal = {Cancers},
year = {2023},
volume = {15},
number = {4},
pages = {1189},
doi = {10.3390/cancers15041189}
}
EUVIMED